Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659263 · ClinicalTrials.gov registry record · Phase 1
RE104 Clinical Lactation Study
A Phase 1 study, sponsored by Reunion Neuroscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT06659263 is a Phase 1 study that has completed, run by Reunion Neuroscience. The registered enrollment target is 14 participants.
The verdict
NCT06659263, a Phase 1 study, has completed, sponsored by Reunion Neuroscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
Interventions
- DRUG RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2024-11-13 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06659263
The ClinicalTrials.gov registry entry for NCT06659263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reunion Neuroscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RE104 for Injection is the first listed.
NCT06659263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06659263 about?
NCT06659263 is a clinical study titled "RE104 Clinical Lactation Study". The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
What is the current status of trial NCT06659263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2024-11-13. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT06659263?
The interventions under investigation include: RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT06659263?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.